Guardant Health (GH) Tops Q2 EPS by 40c, beats revenue, provides guidance

Guardant Health (NASDAQ: GH) reported Q2 EPS of ($0.82), $0.40 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $137.2 million versus the consensus estimate of $129.41 million.

2023 Guidance:

Guardant Health now expects full year 2023 revenue to be in the range of $545 to $550 million

For earnings history and earnings-related data on Guardant Health (GH) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• RBC Capital Starts Guardant Health (GH) at Outperform, 'Underpenetrated Market'
• Guardant Health receives FDA approval for companion diagnostic test